Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: Results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi

Leukemia and Lymphoma

Volumn 53, Issue 4, 2012, Pages 581-588

  Merli, Francesco ^a   Luminari, Stefano ^b   Rossi, Giuseppe ^c   Mammi, Caterina ^a   Marcheselli, Luigi ^b   Tucci, Alessandra ^c   Ilariucci, Fiorella ^a   Chiappella, Annalisa ^d   Musso, Maurizio ^e   Rocco, Alice Di ^f   Stelitano, Caterina ^g   Alvarez, Isabel ^a   Baldini, Luca ^h   Mazza, Patrizio ⁱ   Salvi, Flavia ^j   Arcari, Annalisa ^k   Fragasso, Alberto ^l   Gobbi, Paolo G ^m   Liberati, Anna Marina ⁿ   Federico, Massimo ^b  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c Hematology Unit   (Argentina)

^d Universitaria S Giovanni Battista   (Argentina)

^e Casa di Cura la Maddalena   (Argentina)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g Presidio Ospedali Riuniti Bianchi   (Argentina)

^h UNIVERSITY OF MILAN   (Italy)

ⁱ Hematology   (Argentina)

^j AO SS Antonio e Biagio e Cesare Arrigo   (Argentina)

^k Hematology Unit   (Argentina)

^l Ospedale Madonna delle Grazie   (Argentina)

^m UNIVERSITY OF PAVIA   (Italy)

ⁿ Oncohematology and Autotransplant   (Argentina)

more..

Author keywords

Diffuse large B cell lymphoma; Elderly; Fit patients; R CHOP; R miniCEOP

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; PREDNISONE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; BLADDER CARCINOMA; CANCER PATIENT; CANCER SCREENING; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG FATALITY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GERIATRIC ASSESSMENT; HUMAN; INFECTION; LARGE CELL LYMPHOMA; MALE; NEUTROPENIA; PANCREAS CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 84859094786     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.621565     Document Type: Article

References (30)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO classifi cation of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
2. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin ' s lymphoma. N Engl J Med 1993;328:1002-1006.
3. Coiffi er B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diff use large-B-cell lymphoma. N Engl J Med 2002;346:235-242.
4. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diff use large B-cell lymphoma:a study by the Groupe d ' Etude des Lymphomes de l' Adulte. J Clin Oncol 2005;23:4117-4126.
5. Merli F, Bertini M, Luminari S, et al. Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing mini-CEOP vs P-VEBEC in elderly patients with diff use large B-cell lymphoma. Leuk Lymphoma 2007;48:367-373.
6. Zinzani PL, Gherlinzoni F, Storti S, et al. Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin ' s lymphoma patients. Ann Oncol 2002;13:1364-1369.
7. Luminari S, Montanini A, Caballero D, et al. Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diff use large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial. Ann Oncol 2010;21:1492-1499.
8. Peyrade F, Jardin F, Gisselbrecht C, et al. Rituximab and reduced dose CHOP (R-mini-CHOP) for patients over 80 years with diff use large B-cell lymphoma (DLBCL) - Groupe d ' Etude Des Lymphomes De l ' Adulte (GELA) Study LNH03-7B. Blood 2010;116(Suppl. 1): Abstract 853.
9. Balducci L, Beghe C. Th e application of the principles of geriatrics to the management of the older person with cancer. Crit Rev Oncol Hematol 2000;35:147-154.
10. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007;25:1824-1831.
11. Miller MD, Towers A. A manual of guidelines for scoring the cumulative illness rating scale for geriatrics (CIRS-G). Pittsburg, PA: University of Pittsburg; 1991.
12. Apredictive model for aggressive non-Hodgkin' s lymphoma. Th e International Non-Hodgkin ' s Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-994.
13. Cheson BD, Horning SJ, Coiffi er B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin ' s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
14. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
15. Hryniuk WM. Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 1987;14:65-74.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
17. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187-202.
18. Armitage P, Berry G. Statistical methods in medical research. Oxford, UK: Blackwell; 1987.
19. Wang R, Lagakos SW, Ware JH, et al. Statistics in medicine- reporting of subgroup analyses in clinical trials. N Engl J Med 2007;357:2189-2194.
20. Shoenfeld D. Partial residuals for the proportional hazard regression model. Biometrika 1982;69:239-241.
21. Coiffi er B, Th ieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the fi rst randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d ' Etudes des Lymphomes de l' Adulte. Blood 2010;116:2040-2045.
22. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diff use large B-cell lymphoma. J Clin Oncol 2006;24:3121-3127.
23. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105-116.
24. Marcos-Gragera R, Allemani C, Tereanu C, et al. Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project. Haematologica 2011;96:720-728.
25. Sonneveld P, de Ridder M, van der Lelie H, et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diff use non-Hodgkin ' s lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995;13:2530-2539.
26. Tirelli U, Errante D, Van Glabbeke M, et al. CHOP is the standard regimen in patients+or+70 years of age with intermediate-grade and high-grade non-Hodgkin ' s lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 1998;16:27-34.
27. Bastion Y, Blay JY, Divine M, et al. Elderly patients with aggressive non-Hodgkin ' s lymphoma: disease presentation, response to treatment, and survival-a Groupe d ' Etude des Lymphomes de l ' Adulte study on 453 patients older than 69 years. J Clin Oncol 1997;15:2945-2953.
28. Hryniuk W, Frei E 3rd, Wright FA. A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity. J Clin Oncol 1998;16:3137-3147.
29. Advani RH, Chen H, Habermann TM, et al. Comparison of conventional prognostic indices in patients older than 60 years with diff use large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). Br J Haematol 2010;151:143-151.
30. Monfardini S, Ferrucci L, Fratino L, et al. Validation of a multidimensional evaluation scale for use in elderly cancer patients. Cancer 1996;77:395-401.